度戈妥珠單抗
化合物
度戈妥珠單抗（INN：Duligotuzumab）是一種雙特異性人源化IgG1單株抗體，設計用於治療癌症。它充當免疫調節劑並與EGFR和HER3結合。[1][2]它由羅氏公司開發。針對頭頸癌和結直腸癌的臨床開發已停止，但與考比替尼聯合使用的I期試驗正在評估實體瘤治療的安全性。[3]
| 單株抗體 | |
|---|---|
| 種類 | 完整抗體 |
| 目標 | HER3 |
| 臨床資料 | |
| ATC碼 |
|
| 識別資訊 | |
| CAS號 | 1314238-96-4 |
| ChemSpider |
|
| UNII | |
| KEGG | |
參考資料
- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 (PDF). WHO Drug Information. 2012, 26 (2) [2024-01-22]. （原始內容存檔 (PDF)於2016-03-04）.
- ^ Hill, Andrew G.; Findlay, Michael P.; Burge, Matthew E.; Jackson, Christopher; Alfonso, Pilar Garcia; Samuel, Leslie; Ganju, Vinod; Karthaus, Meinolf; Amatu, Alessio; Jeffery, Mark; Bartolomeo, Maria Di. Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2018-05-15, 24 (10) [2024-01-22]. ISSN 1557-3265. PMID 29506988. doi:10.1158/1078-0432.CCR-17-0646. （原始內容存檔於2024-03-14）.
- ^ Duligotuzumab. AdisInsight. [2024-01-22]. （原始內容存檔於2021-11-19）.